New antifungal drug APX001 gets first human safety check

NCT ID NCT02957929

Completed Knowledge-focused Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 1 trial tested the safety and tolerability of a new antifungal drug called APX001 in 46 healthy volunteers. Researchers gave single and multiple doses, both orally and intravenously, to see how the body handles the drug and whether food affects it. The study also looked at potential interactions with other drugs. Since this is an early-stage trial, it focuses on safety and drug processing, not on treating fungal infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APX001
What this could lead to: If successful, this could pave the way for a new oral or IV treatment for serious fungal infections.
What could go wrong: This is a very early Phase 1 trial in only 46 healthy people, not patients. It only checks safety and how the drug moves through the body, not whether it actually fights infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fungal infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FUNGAL INFECTION

Contacts and locations

Locations

PRA Health Sciences

Groningen, Netherlands
PRA Health Sciences (PRA) - Early Development Services (EDS)

Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.